Natera, Inc.

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
90.46 USD +0.51% Intraday chart for Natera, Inc. -2.63% +44.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer CI
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $824,092, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $16,694,485, According to a Recent SEC Filing MT
Natera Receives Commercial Insurance Coverage of Genetic Test for Transplant Risks MT
Piper Sandler Raises Natera's Price Target to $110 From $70, Maintains Overweight Rating MT
Transcript : Natera, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-06-2024 09:50 AM
Transcript : Natera, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 02:15 PM
Natera Insider Sold Shares Worth $4,478,268, According to a Recent SEC Filing MT
UBS Adjusts Natera Price Target to $104 From $70, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Natera to $100 From $87, Maintains Buy Rating MT
Natera Narrows Q4 Loss, Revenue Rises; Shares Rise Late as 2024 Revenue Outlook Beats Consensus MT
Transcript : Natera, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (NTRA) NATERA Posts Q4 Revenue $311.1M, vs. Street Est of $287.3M MT
Natera Guides For 2024 Revenue of $1.32-$1.35 Billion, vs CIQ Analyst Consensus of $1.27 Billion MT
Natera, Inc. Provides Earnings Guidance for the Year 2024 CI
Natera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Medicare Extends Coverage of Natera's Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer CI
North American Morning Briefing : Stock Futures -2- DJ
Raymond James Downgrades Natera to Outperform From Strong Buy, Raises Price Target to $85 From $68 MT
Natera Insider Sold Shares Worth $6,514,371, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $2,383,129, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $1,509,081, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $277,614, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $964,194, According to a Recent SEC Filing MT
Chart Natera, Inc.
More charts
Natera, Inc. is a diagnostics company that is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women's health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Preimplantation Genetics, Anora Miscarriage Test (Anora) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company's algorithms and bioinformatics in order to validate and launch tests based on the Company's technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
90.46 USD
Average target price
95.41 USD
Spread / Average Target
+5.47%
Consensus